drugset / Trial / NCT05113368
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2026-09
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |